. Author manuscript; available in PMC: 2011 Dec 19.

Published in final edited form as: Nat Rev Immunol. 2010 Apr;10(4):248–256. doi: 10.1038/nri2742

Table 2.

Antitumour and pro-tumour activities of IL-17 and IL-23

Cytokine	model system	Antitumour or pro-tumour effects	Refs
IL-17	Nude or SCID mice	Enhanced tumour vascularization and tumour growth	71–73
IL-17	Immune-competent mice	Enhanced antitumour immunity	60,61
IL-23	IL-23-deficient mice	Reduced MMP9 expression, tumour angiogenesis and fewer chemically-induced tumours	77
	IL-23-transfected B16F10 cells	Enhanced antitumour immunity; the effects are IFNγ and/or CD8⁺ T cell dependent	78
	IL-23-transduced DCs		81
	IL-23-expressing bone marrow cells		79
	Liver IL-23 overexpression and gp100-specific T cells		80
	Systemic IL-23 treatment		82

DC, dendritic cell; IFNγ, interferon-γ; IL, interleukin; MMP9, matrix metalloproteinase 9; SCID, severe combined immunodeficient.